Analysts Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 Earnings Per Share
Equities research analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report ($0.36) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Aduro BioTech’s earnings, with estimates ranging from ($0.46) to ($0.30). Aduro BioTech posted earnings of ($0.44) per share in the same quarter last year, which would suggest a positive year over year growth rate of 18.2%. The firm is expected to announce its next earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Aduro BioTech will report full year earnings of ($1.28) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.22). For the next financial year, analysts anticipate that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.54) EPS.
A number of analysts recently commented on the company. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the company a “buy” rating in a research report on Wednesday, November 1st. Oppenheimer reduced their price objective on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Wednesday. William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the company a “buy” rating in a research report on Thursday. Finally, BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Aduro BioTech presently has an average rating of “Buy” and an average target price of $17.64.
Aduro BioTech (NASDAQ:ADRO) traded up $0.10 during trading on Friday, reaching $8.20. The company had a trading volume of 1,516,344 shares, compared to its average volume of 499,292. Aduro BioTech has a 12 month low of $6.01 and a 12 month high of $14.05.
In other Aduro BioTech news, CEO Stephen T. Isaacs sold 40,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $10.78, for a total value of $431,200.00. Following the completion of the sale, the chief executive officer now owns 213,921 shares in the company, valued at $2,306,068.38. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Blaine Templeman sold 2,884 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $11.20, for a total value of $32,300.80. Following the completion of the sale, the vice president now owns 58,834 shares of the company’s stock, valued at approximately $658,940.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 316,365 shares of company stock valued at $2,866,691. Company insiders own 6.60% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Harvard Management Co. Inc. bought a new position in shares of Aduro BioTech in the third quarter worth about $69,418,000. JPMorgan Chase & Co. boosted its stake in shares of Aduro BioTech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after acquiring an additional 275,295 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Aduro BioTech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after acquiring an additional 160,800 shares during the period. Nexthera Capital LP bought a new position in shares of Aduro BioTech in the second quarter worth about $1,767,000. Finally, Baillie Gifford & Co. boosted its stake in shares of Aduro BioTech by 45.8% in the second quarter. Baillie Gifford & Co. now owns 422,700 shares of the biotechnology company’s stock worth $4,819,000 after acquiring an additional 132,700 shares during the period. Institutional investors and hedge funds own 45.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 Earnings Per Share” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/analysts-anticipate-aduro-biotech-inc-adro-to-post-0-36-earnings-per-share/1768352.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with Analyst Ratings Network's FREE daily email newsletter.